Comparative Pharmacology
Head-to-head clinical analysis: HC 1 versus SERNIVO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HC 1 versus SERNIVO.
HC #1 vs SERNIVO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Unknown
SERNIVO (clobetasol propionate) is a corticosteroid that exerts anti-inflammatory, antipruritic, and vasoconstrictive effects through induction of phospholipase A2 inhibitory proteins, collectively called lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.
Hydrocortisone: 100-200 mg IV as initial dose, then 50-100 mg IV every 6 hours, or 0.18 mg/kg/h IV continuous infusion.
Apply a thin layer to affected area twice daily for up to 2 weeks.
None Documented
None Documented
2–4 hours (terminal); prolonged in renal impairment.
Approximately 3 hours (parent drug); clinical duration extended via formulation.
Renal: 90% as unchanged drug; fecal: 10%.
Primarily renal excretion of inactive metabolites; <5% unchanged. Minor biliary/fecal elimination.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid